The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiology's Annual Scientific Sessions

Monday, March 19, 2012

Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiology's Annual Scientific Sessions09:00 EDT Monday, March 19, 2012NEW BRUNSWICK, N.J., March 19, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Monday, March 26th at approximately 10:30 a.m., Eastern Time, to coincide with the American College of Cardiology (ACC) Annual Scientific Sessions in Chicago, Ill.  Phase 3 results of the EINSTEIN-PE study in treating patients with acute symptomatic pulmonary embolism for the prevention of recurrent venous thromboembolism comparing rivaroxaban to today's standard of care, the combination of initial therapy with enoxaparin followed by Vitamin k antagonist, will be shown for the first time at ACC.A pre-recorded webcast, with management from the company's subsidiaries, Janssen Research & Development, LLC, and Janssen Pharmaceuticals, Inc., will provide an update on the results of the EINSTEIN-PE study and an update on the initial launch of XARELTO® (rivaroxaban). The webcast/podcast and replay can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations."SOURCE Johnson & JohnsonFor further information: Press, Al Wasilewski, +1-732-524-1130, or Bill Price, +1-732-524-6623, or Investors, Stan Panasewicz, +1-732-524-2524, or Louise Mehrotra, +1-732-524-6491